Home LiteratureArticle Details
PMID: 18625748 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease.

The Journal of experimental medicine ·Vol. 205 ·No. 8 ·2008-08-04 ·Pages 1869-77

Björkqvist M, Wild EJ, Thiele J, Silvestroni A, Andre R, Lahiri N, Raibon E, Lee RV, Benn CL, Soulet D, Magnusson A, Woodman B, Landles C, Pouladi MA, Hayden MR, Khalili-Shirazi A, Lowdell MW, Brundin P, Bates GP, Leavitt BR, Möller T, Tabrizi SJ

Abstract

Huntington's disease (HD) is an inherited neurodegenerative disorder characterized by both neurological and systemic abnormalities. We examined the peripheral immune system and found widespread evidence of innate immune activation detectable in plasma throughout the course of HD. Interleukin 6 levels were increased in HD gene carriers with a mean of 16 years before the predicted onset of clinical symptoms. To our knowledge, this is the earliest plasma abnormality identified in HD. Monocytes from HD subjects expressed mutant huntingtin and were pathologically hyperactive in response to stimulation, suggesting that the mutant protein triggers a cell-autonomous immune activation. A similar pattern was seen in macrophages and microglia from HD mouse models, and the cerebrospinal fluid and striatum of HD patients exhibited abnormal immune activation, suggesting that immune dysfunction plays a role in brain pathology. Collectively, our data suggest parallel central nervous system and peripheral pathogenic pathways of immune activation in HD.

MeSH Terms
Animals Case-Control Studies Central Nervous System/immunology,pathology Cytokines/blood,cerebrospinal fluid Gene Expression Humans Huntingtin Protein Huntington Disease/genetics,immunology,pathology Macrophages/immunology,metabolism Mice Mice, Transgenic Microglia/immunology,metabolism Models, Immunological Monocytes/immunology,metabolism Mutation Nerve Tissue Proteins/genetics,immunology,metabolism Nuclear Proteins/genetics,immunology,metabolism Trinucleotide Repeat Expansion
Chemicals
Cytokines HTT protein, human Htt protein, mouse Huntingtin Protein Nerve Tissue Proteins Nuclear Proteins
Authors & Affiliations
22 authors, click to expand affiliations / ORCID
Björkqvist Maria
Neuronal Survival Unit, Department of Experimental Medical Sciences, Wallenberg Neuroscience Center, Lund University, S-221 00 Lund, Sweden.
Wild Edward J
Thiele Jenny
Silvestroni Aurelio
Andre Ralph
Lahiri Nayana
Raibon Elsa
Lee Richard V
Benn Caroline L
Soulet Denis
Magnusson Anna
Woodman Ben
Landles Christian
Pouladi Mahmoud A
Hayden Michael R
Khalili-Shirazi Azadeh
Lowdell Mark W
Brundin Patrik
Bates Gillian P
Leavitt Blair R
Möller Thomas
Tabrizi Sarah J
References (33)
33 references, click to expand
  1. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins.
    Nat Med. 2007 Nov;13(11):1359-62 PMID: 17934472
  2. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length.
    Clin Genet. 2004 Apr;65(4):267-77 PMID: 15025718
  3. Testicular degeneration in Huntington disease.
    Neurobiol Dis. 2007 Jun;26(3):512-20 PMID: 17433700
  4. The Hdh(Q150/Q150) knock-in mouse model of HD and the R6/2 exon 1 model develop comparable and widespread molecular phenotypes.
    Brain Res Bull. 2007 Apr 30;72(2-3):83-97 PMID: 17352931
  5. Multiple comparisons and related issues in the interpretation of epidemiologic data.
    Am J Epidemiol. 1995 Nov 1;142(9):904-8 PMID: 7572970
  6. Activation of the IkappaB kinase complex and nuclear factor-kappaB contributes to mutant huntingtin neurotoxicity.
    J Neurosci. 2004 Sep 15;24(37):7999-8008 PMID: 15371500
  7. Microglial activation in presymptomatic Huntington's disease gene carriers.
    Brain. 2007 Jul;130(Pt 7):1759-66 PMID: 17400599
  8. Microglial activation correlates with severity in Huntington disease: a clinical and PET study.
    Neurology. 2006 Jun 13;66(11):1638-43 PMID: 16769933
  9. Glial cells as intrinsic components of non-cell-autonomous neurodegenerative disease.
    Nat Neurosci. 2007 Nov;10(11):1355-60 PMID: 17965655
  10. The meaning and use of the area under a receiver operating characteristic (ROC) curve.
    Radiology. 1982 Apr;143(1):29-36 PMID: 7063747
  11. Neurological abnormalities in a knock-in mouse model of Huntington's disease.
    Hum Mol Genet. 2001 Jan 15;10(2):137-44 PMID: 11152661
  12. Combination of serum markers related to several mechanisms in Alzheimer's disease.
    Neurobiol Aging. 2003 Nov;24(7):893-902 PMID: 12928047
  13. Predict-HD and the future of therapeutic trials.
    Lancet Neurol. 2006 Sep;5(9):724-5 PMID: 16914400
  14. Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity.
    J Cell Biol. 2005 Dec 19;171(6):1001-12 PMID: 16365166
  15. Weight changes in Huntington's disease.
    Eur J Neurol. 2006 Aug;13(8):e7 PMID: 16879284
  16. Adipokines and the blood-brain barrier.
    Peptides. 2007 Jun;28(6):1317-30 PMID: 17540480
  17. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG.
    Neurology. 2006 Jan 24;66(2):250-2 PMID: 16434666
  18. Increased cytotoxic potential of microglia from ALS-transgenic mice.
    Glia. 2004 Nov 1;48(2):179-82 PMID: 15378658
  19. Early and progressive accumulation of reactive microglia in the Huntington disease brain.
    J Neuropathol Exp Neurol. 2001 Feb;60(2):161-72 PMID: 11273004
  20. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice.
    Cell. 1996 Nov 1;87(3):493-506 PMID: 8898202
  21. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.
    Leukemia. 2003 Dec;17(12):2318-57 PMID: 14562125
  22. Intravenous immunoglobulins in refractory childhood-onset epilepsy: effects on seizure frequency, EEG activity, and cerebrospinal fluid cytokine profile.
    Epilepsia. 2007 Sep;48(9):1739-1749 PMID: 17521345
  23. Expression and biologic characterization of the murine chemokine KC.
    J Immunol. 1995 Jun 1;154(11):6048-57 PMID: 7751647
  24. Regional and cellular gene expression changes in human Huntington's disease brain.
    Hum Mol Genet. 2006 Mar 15;15(6):965-77 PMID: 16467349
  25. A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease.
    Nat Genet. 2005 May;37(5):526-31 PMID: 15806102
  26. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease.
    Hum Mol Genet. 2003 Jul 1;12(13):1555-67 PMID: 12812983
  27. Unified Huntington's Disease Rating Scale: reliability and consistency. Huntington Study Group.
    Mov Disord. 1996 Mar;11(2):136-42 PMID: 8684382
  28. Complement expression in human brain. Biosynthesis of terminal pathway components and regulators in human glial cells and cell lines.
    J Immunol. 1995 May 1;154(9):4726-33 PMID: 7536777
  29. Pharmacological analysis of signal transduction pathways required for mycobacterium tuberculosis-induced IL-8 and MCP-1 production in human peripheral monocytes.
    Cytokine. 2002 Sep 7;19(5):242-9 PMID: 12393171
  30. Cerebrospinal fluid IL-6, HSP72, and TNF-alpha in exercising humans.
    Brain Behav Immun. 2006 Nov;20(6):585-9 PMID: 16647242
  31. Formation of polyglutamine inclusions in non-CNS tissue.
    Hum Mol Genet. 1999 May;8(5):813-22 PMID: 10196370
  32. Progressive alterations in the hypothalamic-pituitary-adrenal axis in the R6/2 transgenic mouse model of Huntington's disease.
    Hum Mol Genet. 2006 May 15;15(10):1713-21 PMID: 16613897
  33. Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates.
    J Proteome Res. 2007 Jul;6(7):2833-40 PMID: 17552550
Article Info
Journal
The Journal of experimental medicine
Abbr.
J Exp Med
ISSN
1540-9538
Published
2008-08-04
Epub
2008-00-14
Pages
1869-77
Language
English
Region
United States
NLM ID
2985109R
PMCID
PMC2525598
Subset
IM
Grants
Wellcome Trust · United Kingdom
Medical Research Council · G0700877 · United Kingdom
Wellcome Trust · 66270 · United Kingdom
Department of Health · United Kingdom
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com